Kornimate/medical-research-clean huggingface dataset:
comparing two mandibular positioning techniques for dental sleep appliances

Conditions: Sleep Apnea, Obstructive; Occlusal Splints

Summary: this is a prospective study that directly compares the use of speech vs an anterior protrusive technique for mandibular positioning.

obstructive sleep apnea is a medical condition where a person has great difficulty with breathing, or stops breathing all together, while asleep. this is a medical condition for which one of the current standard treatments is the use of a custom-made dental appliance to help hold the person's airway open while asleep so that the person does not suffocate while sleeping. current methodology within dentistry is to position the mandible based on the person's maximum ability to position their mandible forward as the starting point and then slowly move the bottom jaw forward as necessary. recent literature has shown that different mandibular positioning techniques may require less protrusion, less titrations, and potentially decreased side effects compared with the traditional protrusive techniques. one of the most promising techniques involves the use of speech to determine mandibular position. this technique would not require that a patient place their jaw outside of their normal functional range and could potentially decrease the face pain/jaw joint problems commonly associated with the use of oral sleep appliances for the treatment of obstructive sleep apnea. the use of speech as the determinant for where to position the mandible is important for muscular balance. minimal research has been done in this area, with most studies being either retrospective or confounded by other variables. this will be the first prospective study that directly compares the use of speech vs an anterior protrusive technique for mandibular positioning.

Eligibility criteria:
inclusion criteria: patient diagnosed with obstructive sleep apnea, and * prescription/order for a dental sleep appliance * 18 years or older * treatment planned in accordance with aadsm treatment guidelines exclusion criteria: * there are no separate exclusion criteria
safety and effectiveness of soy phytoestrogens to prevent bone loss

Conditions: Osteoporosis

Summary: the purpose of this study is to determine whether soy isoflavone supplementation is safe and effective to prevent bone loss in postmenopausal women.

over-the-counter soy isoflavone supplement usage is becoming common among postmenopausal women. however, there is no documented scientific evidence of its long-term safety and efficacy in preventing osteoporosis. our primary goal is to determine the safety, efficacy, and optimal dosage of isoflavone supplementation to reduce bone loss in postmenopausal women. the multi-state, multi-institutional design ensures that the study results are representative of postmenopausal women in the u.s. population. confirming the skeletal benefits of soy isoflavones could translate into reduced healthcare costs related to osteoporosis.

Eligibility criteria:
inclusion criteria: * must be able to swallow the pills * no menses for 12 months * blood follicle stimulating hormone great than 30 iu/ml * lumbar spine bone mineral density t-score equal to or greater than -1.5 exclusion criteria: * strict vegetarians * current or recent smokers (within last five years) * abnormal screening mammogram, pap smear and blood chemistries * clinical diagnosis of osteoporosis, spine and/or hip fracture, cancer, liver, kidney, gallbladder and heart disease * clinical diagnosis of psychiatric disorder * any allergic reactions to soy products * current treatment with bisphosphonates, calcitonin, fluoride, corticosteroids, tamoxifen, raloxifene, hrt, premarin, farestron and letrozole * current usage of black cohosh, blue cohosh, dong quai, caltrate 600+soy, estroven, ginseng, healthy women, natural estrogen, opti-soy, phytofem, probalance, promensil, remifemin, rimostil and trinovin

Keywords: osteoporosis soy isoflavones postmenopausal women safety efficacy effective dosage
metabolomic and immune profiling in the development of pancreatic fistulas after cephalic duodenopancreatectomy

Conditions: Pancreatic Fistula; Acute Pancreatitis; Pancreatoduodenectomy

Summary: pancreatoduodenectomy is the standard surgical operation for benign or malign pancreatic lesions. pancreatic fistula (pf) or postpancreatectomy acute pancreatitis (ppap) are the major complications associated with that type of surgery. we need to develop preventive measures for these complications, which requires a better understanding of their physiopathology. the aim of this prospective monocentric and observational study is to identify predictive biomarkers and/or risk factors for pf or ppap using metabolomics. the profiling of circulating metabolites is indeed an original and promising approach for this purpose. we will also investigate the patient's immune status and its association with the occurrence of post-surgical complications. participants will be adult patients scheduled to undergo elective pancreaticoduodenectomy. surgery and patient's management will be as usual. during surgery, a fragment (0.1-0.2 g) of non-tumoral pancreatic tissue will be removed and frozen at -80°c for metabolomic analysis. for immunological assessment, 4 blood samples will be collected (before surgery and then 7 days, 1 and 3 months after, blood sampling).


Eligibility criteria:
inclusion criteria: * patients scheduled to undergo elective pancreaticoduodenectomy * non-opposition of the subject to participate in the study. * affiliated to the french social security system (cmu included). exclusion criteria: * emergent surgery. * pregnant patients. * refusal to participate or inability to provide informed consent. * patient under legal protection (individuals under guardianship by court order).

Keywords: metabolomics immune response pancreatic fistula pancreatoduodenectomy
pedometer use to prevent excessive pregnancy weight gain in overweight women

Conditions: Overweight; Obesity; Pregnancy

Summary: the purpose of this study is to evaluate pedometer use by overweight women during pregnancy. the study will show if a pedometer will help women to limit weight gain during pregnancy. it will also show if it there are other benefits such as decreased diabetes, decreased high blood pressure, decreased rates of cesarean section, and decreased complications for the baby.


Eligibility criteria:
inclusion criteria: * age 18 years or older * pregnant * less than 16 weeks gestation * body mass index 25 or greater at first prenatal visit exclusion criteria: * history of spontaneous preterm delivery between 20-32 weeks gestation * medical contraindication to exercise or walking during pregnancy

Keywords: overweight obesity pregnancy weight gain pedometer exercise
dwp708 for treating epidermal growth factor receptor inhibitor related skin toxicities

Conditions: Rash Acneiform

Summary: a multi-center, randomized, double-blind, placebo-controlled, therapeutic exploratory, phase ii clinical trial for the efficacy investigation and safety evaluation of dwp708 for treating rash acneiform

all the patients had grade ≥2 erses according to the national cancer institute's common terminology criteria for adverse events (nci-ctcae) v. 5.0

Eligibility criteria:
inclusion criteria: 1. age: older than 19 2. eastern cooperative oncology group (ecog) performance status 0 -2 3. patients who have rash acneiform gr≥2 (nci ctcae v5.0) 4. patients who are currently administering egfr tki or egfr mab exclusion criteria: 1. known allergies, hypersensitivity, or intolerance to study drugs, chemotherapy drugs using this clinical trial 2. patients with a history of topical medication * steroids within 3 days prior to baseline visit * antihistamine, antipruritic agents, antibiotics agents within 1 week prior to baseline visit * tacrolimus, pimecrolimus within 2 weeks prior to baseline visit
sleep quality and related factors in hemodialysis patients

Conditions: Haemodialysis-induced Symptom

Summary: sleep quality is an important predictor of healthy status,quality of life and life span. sleeping problems affect 50%\~80% in hemodialysis patients. sleep quality and related factors research in hemodialysis patients has been discussed and studied globally. previous studies show insomnia, excessive daytime sleepiness(eds), sleep apnea syndrome(sas), restless legs syndrome(rls) are major causes of poor sleep quality . there is few data to show the influential factors related to sleep quality in taiwanese hemodialysis patients.

this study will be a cross-sectional design with purposive sample from 2 different dialysis medical centers in taipei. two hundred hemodialysis patients meeting inclusion criteria will be recruited.

Eligibility criteria:
inclusion criteria: * hemodialysis patient whose age ≧ 20 years old and conscious clear. * icd9：585.6 * every week receives two or three convention hemodialysis treatment above three months. * may communication with mandarin or taiwanese language. * patient or caregiver is willing to participate study and sign the inform consent. exclusion criteria: * hospitalized hemodialysis patient in recently one month. * hemodialysis patient had conscious disturbance, blind or dementia. * hemodialysis patient refuse to interview or fill out questionnaires.

Keywords: hemodialysis patients sleep quality restless legs syndrome excessive daytime sleepiness sleep apnea syndrome
a study to evaluate the efficacy of somatropin in the treatment of patellar tendinopathy

Conditions: Tendinopathy

Summary: patellar tendinopathy is one of the most frequent causes of non-traumatic knee pain and reduced function in patients. standard treatment options for patellar tendinopathies include non-steroidal anti-inflammatory drugs, corticosteroids, cryotherapy, manual therapy, eccentric exercises, and ultrasound. unfortunately many patients fail to respond to these therapies and return to normal activity levels, and recurrence rates for those who do respond are unacceptably high. many patients who fail to respond display persistent degenerative changes on imaging studies suggesting a failure to regenerate the pathological tissue. developing new therapies that can directly promote the synthesis of new, healthy extracellular matrix tissue could therefore address an important therapeutic need and make a substantial improvement in our ability to effectively treat patellar tendinopathy and reduce recurrence rates. somatropin (human growth hormone of recombinant dna origin) has been shown to increase protein synthesis and matrix production when delivered directly into the tendon. this study will evaluate the ability of somatropin to improve clinical outcomes and tissue quality in patients with chronic tendinopathy.


Eligibility criteria:
inclusion criteria: * males and females ages 18 - 50 * patients with a greater than 3 month history of anterior knee pain * patients with a confirmed diagnosis of patellar tendinopathy (confirmation by ultrasonography demonstrating local anterior-posterior thickening of the tendon of at least 1mm compared with the mid-tendon level, and a hypo-echoic area) exclusion criteria: * patients who have received corticosteroid injections within 12 months * patients who have full-width disruptions of the patellar tendon * patients who have undergone previous knee surgery or intraarticular injury * patients who have have arthritis (kellgren and lawrence grade 2 or higher), open growth plates, diabetes, cardiovascular disease, history of cancer or any major medical illnesses or endocrine disorders * patients with a body mass index greater than 35 * women who are pregnant or planning to become pregnant * patients who are current collegiate, professional or elite athletes, or are participating in sports organizations that currently ban the use of somatropin

Keywords: patellar tendinopathy somatropin jumper's knee
a study of pegylated interferon alfa-2b (mk-4031) as an adjuvant treatment in japanese patients with malignant melanoma (mk-4031-370)

Conditions: Malignant Melanoma

Summary: this is a study to evaluate the safety and tolerability of peginterferon alfa-2b (pegifn alfa-2b) as adjuvant treatment in japanese participants with malignant melanoma after definitive surgical resection including complete lymphadenectomy. participants on this study will initially receive pegifn alfa-2b for 8 weeks (induction phase) and then may continue to receive pegifn alfa-2b (maintenance phase) as long as they are experiencing clinical benefit (up to 252 weeks). the primary hypothesis is that peginterferon alfa-2b administered on a weekly basis is safe and tolerated.

the study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in japan.

Eligibility criteria:
inclusion criteria: * stage ii or iii melanoma * primary melanoma completely excised * full lymphadenectomy within 84 days prior to initiation of study treatment * eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * ocular melanoma or melanoma of the mucous membranes * evidence of distant or non-regional lymph node metastases * in-transit melanoma * previously treated with interferon alpha/beta, chemotherapy, hormonal therapy, radiotherapy or immunotherapy/vaccine for melanoma
study of asian patients with hypercholesterolaemia in the uk - rosuvastatin 5mg versus atorvastatin 10mg

Conditions: Hypercholesterolaemia

Summary: the purpose of this study is to compare the effectiveness and safety of rosuvastatin 5mg in lowering blood cholesterol, compared to one other medicine, atorvastatin 10mg in asian patients in the uk.


Eligibility criteria:
inclusion criteria: * self described asian, first or second generation * male or female \> or = 18 years with primary hypercholesterolaemia. exclusion criteria: * use of cholesterol lowering drugs from visit 1 * homozygous familial hypercholesterolaemia * active arterial disease within 3 months of study entry * poorly controlled diabetes * uncontrolled hypothyroidism * active liver disease * history of alcoh/drug abuse.

Keywords: cholesterol statin asian ldl-cholesterol
effects and mechanisms of treatment intensity of mirror therapy in patients with subacute stroke

Conditions: Cerebrovascular Accident

Summary: the purpose of this study will evaluate the long-term benefits, optimal dose and mechanisms of mirror therapy and its effects on physiological markers.

this trial is to examine whether (1) the immediate effects of treatment intensity in mt would occur on sensorimotor impairments and functional performance in patients with subacute stroke; (2) the long-term benefits of treatment intensity in mt on functionality can persist for six months after treatment finished; and (3) the mt could result in cortical/movement reorganization as well as the changes in physiological markers.

Eligibility criteria:
inclusion criteria: * first episode of stroke in cortical regions * time since stroke less than 3 months * initial motor part of ue of fma score ranging from 24 to 52 * no serious cognitive impairment exclusion criteria: * aphasia * visual impairments * major health problems or poor physical conditions * currently participation in any other

Keywords: stroke rehabilitation mirror therapy functional performance kinematic analysis functional magnetic resonance image motor recovery
crossover clinical trial, randomized, double blind, placebo controlled trial

Conditions: Chronic Kidney Disease

Summary: the purpose of this study is to determine the effect of inhibiting xanthine oxidase with allopurinol in patients with chronic kidney disease in asymptomatic hyperuricemia endothelial injury and vascular repair mechanisms.

the purpose of this study is to determine the effect of inhibiting xanthine oxidase with allopurinol in patients with chronic kidney disease in asymptomatic hyperuricemia endothelial injury and vascular repair mechanisms, evaluating the plasma concentration of angiogenic factors, microparticles of endothelial cells and the cell number circulating endothelial progenitor.

Eligibility criteria:
inclusion criteria: * patients willing and able to give informed consent for participation in the study * ability to understand study procedures and to comply with it for the duration of the study. * subjects of both sexes, the age range between 18 and 70 years old. * serum uric acid above 7 mg / dl. * estimated glomerular filtration rate by mdrd abbreviated formula less than 60 ml / min / 1.73 m2 and above 15 ml / min / 1.73 m2. * stability of renal function (serum creatinine increase without exceeding 50% in the three months before the start of the study). * clinically stable in terms of no hospitalizations of cardiovascular events in the 3 months before the study began. exclusion criteria: * drop active in the 60 days prior to study initiation. * use of allopurinol within 60 days preceding baseline * active infections within 30 days prior to baseline. * patients with systemic inflammatory disease * infection with hiv, hepatitis c and hepatitis b. * history of cancer within 5 years prior to the first dose of study medication * chronic liver disease. * immunosuppressive therapy. * pregnant women, breastfeeding or planning to become pregnant. * allergy or sensitive to allopurinol. * addiction to drugs or alcohol, in the opinion of the investigator, may interfere with compliance with study requirements. * inability or unwillingness of the individual or legal guardian or representative to give written informed consent.

Keywords: chronic kidney disease allopurinol ckd
improving bowel function and quality of life after spinal cord injury

Conditions: Neurogenic Bowel

Summary: bowel dysfunction is consistently rated as one of the most common complications affecting daily life for individuals with spinal cord injury. the overall objective of this study is to investigate whether the use of specific spinal cord epidural stimulation will affect bowel function. this study will also examine how alterations in bowel function influence quality of life outcomes. the results of this study may aid in the development of treatments to help individuals with spinal cord injuries that have impaired bowel function.

participants in this study must be enrolled in the ts - epi study (irb# 16.0179) which provides the spinal cord epidural implant and training interventions. you will receive two sets of interventions, each one lasting 80 sessions for a total of 160 sessions. assessments for bowel function and quality of life will be performed as part of this study and are conducted at baseline/pre-training, post-intervention 1, post-intervention 2, and at the 6-month and 12-month follow-ups. your participation in this study will last up to 24 months.

Eligibility criteria:
inclusion criteria: * at least 18 years of age at the time of enrollment * at least 2 years post injury * non-progressive spinal cord injury * stable medical condition * unable to voluntarily move all joints of the legs * unable to stand independently * cardiovascular dysfunction including presence of persistent resting low blood pressures and/or symptoms of autonomic dysreflexia and/or orthostatic hypotension and/or dysregulation in response to postural changes and/or highly variable blood pressures in 24 hour period * bowel dysfunction as a result of spinal cord injury exclusion criteria: * ventilator dependent * untreated painful musculoskeletal dysfunction, unhealed fracture or pressure sore * untreated psychiatric disorder or ongoing drug abuse * colostomy bag * any implanted pump (i.e., baclofen pump, pain pump, etc) * cardiovascular or bowel dysfunction unrelated to sci * ongoing nicotine use * pregnant at the time of enrollment or planning to become pregnant during the time course of the study

Keywords: bowel spinal cord injury epidural stimulation
a study to determine progression-free survival (pfs) and evaluate participant experience for participants with metastatic anaplastic lymphoma kinase-positive (alk+) non-small cell lung cancer (nsclc) treated with anaplastic lymphoma kinase (alk) inhibitors

Conditions: Anaplastic Lymphoma Kinase-positive; Carcinoma Non-small-cell Lung

Summary: the primary purpose of this study is to determine the differences in pfs for participants who have been receiving brigatinib as alk inhibitor therapy for alk+nsclc compared to those participants receiving alectinib, ceritinib, lorlatinib, or other alk inhibitors that may become available during study treatment.

this is a prospective and non-interventional study of participants with alk+nsclc. the study will seek to determine the real-world differences in the pfs of participants taking brigatinib or any fda approved alk inhibitor other than crizotinib in routine clinical practice and will evaluate participant's quality of life, daily function, general condition, and treatment satisfaction. the study will enroll approximately 160 participants: 80 participants taking brigatinib, and 80 participants taking fda approved alk inhibitors other than crizotinib. participants will be enrolled in one of the 2 cohorts: * brigatinib * any fda approved alk inhibitor other than crizotinib this trial will be conducted in the united states. upon enrollment into the study, participants will complete a study-specific baseline questionnaire and four validated instrument questionnaires. after that, participants will complete a study-specific monthly questionnaire and four validated instrument questionnaires, which will be made available to participants every 30 days. participants will be sent automatic e-mail reminders every 30 days when new surveys become available. all participants will receive a notice on completion of their participation in the study at approximately 24 months.

Eligibility criteria:
inclusion criteria: 1. has alk+ nsclc. 2. has been prescribed: * brigatinib at any point in therapy, or * any fda approved alk inhibitor at any point in therapy other than crizotinib. participants who were previously on crizotinib, but are now on another alk inhibitor are eligible for study participation. 3. has internet access. 4. is willing to answer regular e-surveys and allow for the prescriber or clinic to provide data on the status of the participant's nsclc. exclusion criteria: 1. has received any investigational compound within 90 days prior to consent.

Keywords: drug therapy